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Helicobacter pylori colonization 
and obesity – a Mendelian 
randomization study
Wouter J. den Hollander1, Linda Broer2, Claudia Schurmann  3,4, David Meyre5,6, Caroline 
M. den Hoed1, Julia Mayerle7, Albert Hofman8,10, Georg Homuth9, André G. Uitterlinden2,8, 
Markus M. Lerch7 & Ernst J. Kuipers1,2
Obesity is associated with substantial morbidity, costs, and decreased life expectancy, and continues 
to rise worldwide. While etiological understanding is needed for prevention, epidemiological studies 
indicated that colonization with Helicobacter pylori (H. pylori) may affect body mass index (BMI), but 
with inconsistent results. Here, we examine the relationship between H. pylori colonization and BMI/
obesity. Cross-sectional analyses were performed in two independent population-based cohorts of 
elderly from the Netherlands and Germany (n = 13,044). Genetic risk scores were conducted based on 
genetic loci associated with either H. pylori colonization or BMI/obesity. We performed a bi-directional 
Mendelian randomization. Meta-analysis of cross-sectional data revealed no association between 
anti-H. pylori IgG titer and BMI, nor of H. pylori positivity and BMI. Anti-H. pylori IgG titer was negatively 
associated with obesity (OR 0.99972; 95% CI 0.99946-0.99997, p = 0.03) and with obesity classes (Beta 
−6.91 •10−5; 95% CI −1.38•10−4, −5.49•10−7, p = 0.048), but the magnitude of these effects was 
limited. Mendelian randomization showed no causal relation between H. pylori genetic risk score and 
BMI/obesity, nor between BMI or obesity genetic risk scores and H. pylori positivity. This study provides 
no evidence for a clinically relevant association between H. pylori and BMI/obesity.
The prevalence of obesity rises worldwide. This is associated with significant morbidity, costs, and decreased life 
expectancy. The latter can be reduced with 8-13 years1, which results in a huge economic burden2. The causes of 
obesity are diverse and include excessive energy intake, lack of physical activity, but also culprits such as stress, 
lack of sleep, or exposure to chemical endocrine disruptors3. There is increasing evidence from mouse as well 
as human studies that shows that the gut microbiome may play an important role in energy balance4. Modern 
lifestyle, and the widespread use of antibiotics may affect the composition of our microbiome, which may have 
consequences for our health5.
In this context, Helicobacter pylori (H. pylori), is of relevance. This Gram-negative, spiral-shaped, gastric bac-
terium is gradually disappearing in Western populations5,6. H. pylori colonization is virtually always associated 
with chronic active gastritis, which can have various effects. This includes interference with gastric hormone 
regulation, including ghrelin and leptin. Both have multiple roles in energy homeostasis7. Disturbance of their 
normal regulation interferes with metabolism and our energy household. H. pylori eradication increases serum 
ghrelin levels8.
For these reasons, several epidemiological studies have focused on the correlation between H. pylori coloniza-
tion and BMI and obesity. They showed contrasting results, which were based on H. pylori status and BMI data, 
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but did not include genetic information. A recent genome-wide association study (GWAS) identified two genetic 
loci associated with anti-H. pylori IgG titers9. Numerous GWAS have identified many genetic loci associated with 
BMI variation and/or obesity risk10. Combining these results into risk scores enables a Mendelian randomization 
study for association between H. pylori serology and BMI. Mendelian randomization is a technique that aims at 
unbiased detection of causal effects11.
We aimed to assess the relationship between H. pylori seroprevalence and obesity using both epidemiological 
and genetic data of two population-based cohort studies. Results of cross-sectional and genetic analyses were 
compared. In addition, we performed a meta-analysis of data derived from both cohorts.
Results
Baseline characteristics. In total, 13,044 participants were initially included in this study. Table 1 summa-
rizes the baseline characteristics of each cohort. In 220 subjects (1.7%) no data on BMI was available. Data on 
H. pylori titer was lacking in 252 individuals (1.9%) of SHIP. The total population included in the cross-sectional 
analyses consisted of 12,572 (96.4%) subjects. According to the predefined phenotypic seroprevalence, a total of 
3,147 (25.0%) subjects were considered as cases, and 9,425 (75%) as controls.
Genotyping data was available for 6,883 (86.3%) subjects of RS, for 3,824 (93.7%) subjects of SHIP, and for 983 
(99.7%) of SHIP-TREND, leaving a total population for analysis of 11,690 (89.6%) subjects. Table 1 summarizes 
the mean gene risk score for each cohort with respect to the correlation between BMI, obesity, and H. pylori. 
Linear regression analysis within RS focusing on the BMI gene score and BMI revealed a beta of 0.10 kg/m2 per 
additional BMI-increasing allele (95% CI 0.07–0.12, p = 5.29•10−16). Logistic regression analysis focusing on the 
obesity gene score and obesity (BMI ≥ 30 kg/m2) revealed an OR of 1.04 per additional obesity risk allele (95% CI 
1.02–1.05, p = 1.09•10−4). The H. pylori gene score was significantly associated with H. pylori positivity (OR 1.39, 
95% CI 1.27–1.51; p = 3.46•10−13). The proportion of variance of BMI, obesity, and H. pylori explained by the 
genetic risk scores ranged from 0.3% for obesity, 0.5% for H. pylori and 1% for BMI per 1 unit increase in score.
Cross-sectional analyses. Cross-sectional analyses revealed an association between H. pylori titer and BMI 
in RS and SHIP (Supplementary Table S1), however with opposite direction. Meta-analysis of all three cohorts 
showed no association between H. pylori titer and BMI, nor between H. pylori positivity and BMI (Table 2). H. 
pylori titer, adjusted for age and sex, was negatively associated with obesity (OR 0.99; 95% CI 0.99–1.00, p = 0.03) 
and with obesity classes (Beta −6.91 •10−5; 95% CI −1.38•10−4, −5.49•10−7, p = 0.048) (Table 2).
Cross-sectional analyses regarding fecal H. pylori status and BMI/obesity showed no association 
(Supplementary Table S2).
Cohort RS-I and RS-II SHIP SHIP-TREND
Total number (n) 7,977 4,081 986
Age (years), mean (sd) 69.0 (9.3) 49.7 (16.3) 50.1 (13.7)
Female sex (%) 4,391 (55.0) 2,073 (50.8) 554 (56.2)
H. pylori titer distribution, median (range) 24.3 (6.2–5587.4) 30.4 (5–500) 16.1 (5–500)
H. pylori positive (cut-off)1, % 4,372 (54.8) 2,275 (59.4) 440 (44.8)
H. pylori positive (highest 25% IgG titer)2, % 1,994 (25.0) 958 (25.0) 246 (25.0)
H. pylori antigen distribution, median (range) NA NA −0.004 (−0.151, 3.983)
H. pylori antigen (cut-off)1, % NA NA 255 (26.9)
BMI (kg/m2), mean (sd) 26.7 (3.9) 27.3 (4.7) 27.4 (4.6)
Missing, n (%) 209 (2.6) 11 (0.3) 0 (0.0)
Obesity (BMI ≥ 30), % 1,343 (17.3) 1,042 (25.6) 252 (25.6)
Overweight (BMI ≥ 25), % 5,027 (64.7) 2,690 (66.1) 660 (66.9)
Obesity classes (BMI), %
Lean, <18.5 79 (1.0) 42 (1.0) 2 (0.2)
Normal weight, 18.5–24.9 2,662 (34.3) 1,338 (32.9) 324 (32.9)
Overweight, 25.0–29.9 3,684 (47.2) 1,648 (40.5) 408 (41.4)
Class I obesity, 30.0–34.9 1,110 (14.3) 775 (19.0) 200 (20.3)
Class II obesity, 35.0–39.9 203 (2.6) 217 (5.3) 42 (4.3)
Class III obesity, ≥40.0 30 (0.4) 50 (1.2) 10 (1.0)
BMI risk score, mean (sd) 43.22 (3.98)
Missing, n (%) 1,094 (13.7) 257 (6.3) 3 (0.3)
Obesity risk score, mean (sd) 42.58 (3.94)
Missing, n (%) 1,094 (13.7) 257 (6.3) 3 (0.3)
H. pylori risk score, mean (sd) 3.34 (0.65)
Missing, n (%) 1,094 (13.7) 257 (6.3) 3 (0.3)
Table 1. Baseline characteristics (total cohort n = 13,044). 1According to manufacturer’s definition. 2According 
to phenotype definition. NA, not applicable.
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Mendelian randomization. The BMI gene score was not associated with H. pylori titer or positivity 
(Table 3). Supplementary Table S3 shows the results of each cohort. Crude analysis showed a positive associa-
tion between obesity gene score and H. pylori titer (Beta 0.76; 95% CI 0.02–1.50, p = 0.04) (Table 3). H. pylori 
gene score was not associated with BMI, neither with obesity nor obesity classes (Table 4 and Supplementary 
Table S4). Also, no associations were observed regarding fecal H. pylori status and the BMI or obesity gene score 
(Supplementary Table S5).
Discussion
This study included a meta-analysis of 13,044 subjects from two large population-based cohorts. This analysis 
did not demonstrate an association between H. pylori colonization and BMI, neither when examined by means 
of serology, nor by fecal antigen, or Mendelian randomization. H. pylori serology, adjusted for age and sex, was 
negatively associated with obesity (BMI ≥ 30 kg/m2), and obesity classes. However, these effects were small. Active 
H. pylori colonization, determined by a positive fecal antigen test, was also not positively or negatively associated 
with obesity. While the unadjusted and adjusted effect estimates for the obesity gene score on anti-H. pylori IgG 
titer were positive, this association did not remain statistically significant after adjustment for age and sex. So, the 
use of a Mendelian randomization method did not show a causal bi-directional link between H. pylori serology 
and BMI or obesity.
Our meta-analysis of H. pylori status as determined by serology showed a small negative association with 
both obesity and obesity classes. Considering both the small effect estimates, and opposite directions in the indi-
vidual cohorts, we consider these associations as clinically irrelevant. Prior epidemiological studies have shown 
either negative12, or positive13,14, or no association15,16 between H. pylori and BMI or obesity. The latter findings 
are most in line with our findings. A recent review of studies reporting data on H. pylori and obesity prevalence 
rates in developed countries, showed an inverse correlation (r = −0.29, p < 0.001) between H. pylori colonization 
and obesity and overweight17. In total, data of 99,463 subjects from 49 studies were pooled. Prevalence rates for 
H. pylori, but also for overweight and obesity were highly variable between included studies. Nevertheless, no 
additional analyses were performed to examine whether this correlation was related to potential significant con-
founders such as age. Age is an important confounder as it is positively correlated with H. pylori colonization18, 
and negatively with obesity18. This may explain the negative correlation between H. pylori and obesity reported 
in the systematic review. Other studies have observed weight gain following successful H. pylori eradication19–23. 
A clinical trial from Japan randomized 1,558 H. pylori-positive adults to either antibiotic treatment or placebo 
with a subsequent follow-up of 6 months. H. pylori eradication was associated with a mean weight gain of 0.6 kg 
(95% CI 0.31, 0.88) and an increase in BMI of 0.2 kg/m2 19. The simultaneous improvement of dyspepsia symp-
toms in the eradication group may have stimulated the appetite and subsequently caused the weight gain by 
increased food intake. Others have suggested that circulating meal-associated leptin and ghrelin levels, which 
changed after H. pylori eradication, gave rise to the increased BMI. US investigators observed an increase in both 
post-prandial levels of leptin and ghrelin a median seven months following H. pylori eradication in a group of 
21 patients24. In addition, BMI significantly increased after over 18 months of follow-up, while no change was 
observed in those who were H. pylori-negative at baseline. Although these studies provided evidence that H. 
pylori eradication may result in weight gain, it does not imply that there is an absolute difference in BMI between 
H. pylori-negative and positive subjects. Both our cross-sectional as well as Mendelian randomization results 
suggest that H. pylori-colonized and H. pylori-negative subjects have similar BMI. The congruence between the 
Model Cohort Meta-analysis
BMI~H. pylori RS SHIP SHIP-TREND Beta kg/m2 (95% CI) p-value
Hp titer - crude − + + 1.19•10−3 (−1.61•10−3; 3.99•10−3) 0.39
Hp titer - adjusted1 − + − −3.09•10−4 (−6.46•10−4; 2.81•10−5) 0.07
Hp positivity – crude − + + 0.37 (−0.48; 1.22) 0.40
Hp positivity - adjusted1 − + − 0.04 (−0.34; 0.41) 0.84
Obesity2~H. pylori OR (95% CI)
Hp titer – crude − + + 1.00 (0.99; 1.00) 0.72
Hp titer - adjusted1 − + − 1.00 (0.99; 1.00) 0.03
Hp positivity – crude − + + 1.04 (0.78; 1.39) 0.78
Hp positivity - adjusted1 − + − 0.95 (0.86; 1.06) 0.37
Obesity classes3~H. pylori Beta (95% CI)
Hp titer – crude − + + 2.28•10−4 (−2.91•10−4; 7.48•10−4) 0.39
Hp titer - adjusted1 − + − −6.91 •10−5 (−1.38•10−4; −5.49•10−7) 0.05
Hp positivity – crude − + + 0.06 (−0.10; 0.22) 0.49
Hp positivity - adjusted1 − + − −0.02 (−0.05; 0.02) 0.36
Table 2. Cross-sectional analyses regarding serologic H. pylori status and BMI/obesity – meta-analysis. 
1Adjusted for sex and age. 2Obesity defined as BMI ≥ 30 kg/m2. 3Lean: BMI < 18.5 kg/m2; normal-weight: 
BMI ≥ 18.5 and <25 kg/m2; overweight: BMI ≥ 25 and <30 kg/m2; class I obesity: BMI ≥ 30 and <35 kg/m2;  
class II obesity: BMI ≥ 35 and <40 kg/m2, class III obesity: BMI ≥ 40 kg/m2. ‘−’ means a negative Beta or 
OR < 0.1. ‘+’ means a positive Beta or OR > 0.1.
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results of our cross-sectional and Mendelian randomization analyses is important, as the latter is based on an 
unbiased approach11.
One of the strengths of this study was the use of different methods to detect H. pylori colonization, by means 
of both serology and stool antigen. The latter is a reliable method to identify active H. pylori colonization. While 
most prior studies reported data on serology, we were able to show that results for serology and fecal antigen did 
not differ. In addition, the use of SNP typing data with genetic risk scores for BMI, obesity, and H. pylori coloni-
zation is unique in this field. The Mendelian randomization method is a powerful control for reverse causation 
and confounding, which otherwise affects epidemiological studies11. It is based on the common disease, common 
variant hypothesis, which argues that common variants with modest effects underlie many complex traits25.
As any method, the Mendelian randomization has its limitations. Although many genetic variants are discov-
ered, these common variants only explain a small proportion of the estimated trait heritability. Regarding the H. 
pylori-gene risk score, we were only able to include two genetic variants, due to the fact that no others (as far as 
we know) have been discovered so far, and these explain only 0.5% of the variance. Similarly, a recent large-scale 
consortium study estimates that 97 GWAS loci account for ∼2.7% of BMI variation26. Data on H. pylori eradi-
cation was not available in the RS and SHIP cohort. Nevertheless, given the selective indications for this both in 
The Netherlands and in Germany, we can safely assume that this was a small minority of the total population. 
Finally, we did not account for socio-economic status in the cross-sectional analyses. Although both populations 
are similar regarding ethnicity and age distribution, differences in socio-economic status are associated with both 
H. pylori colonization and BMI, and may therefore have influenced our outcome.
In conclusion, this study provides no evidence for a cross-sectional association between H. pylori colonization 
and BMI or obesity in adults. Mendelian randomization revealed no causal relation between H. pylori and BMI 
or obesity.
Methods
Study cohorts. The Rotterdam Study is a large, population based prospective study of elderly individuals of 
European ancestry consisting of three cohorts (RS-I, RS-II, RS-III), who are residing in a suburb of Rotterdam, 
the Netherlands. The study design has been described in detail previously23,27. Baseline recruitment and meas-
urements for the RS-I study were obtained between 1990 and 1993. The second cohort, RS-II, was set-up in 
2000–2001. A third cohort, RS-III, started in 2006 and recruitment ended in December 2008.
The SHIP study comprises two independent prospectively recruited population-based cohorts in Northeastern 
Germany: SHIP and SHIP-TREND. The study design of SHIP has been described in detail previously18. 
Participants were recruited between October 1997 and May 2001. SHIP-TREND is an independent cohort from 
the same region. Individuals were recruited between September 2008 and summer 201218. An important charac-
teristic of SHIP is that it attempts to describe health-related conditions with the widest focus possible.
Data from SHIP, SHIP-TREND, RS-I, and RS-II (RS from now on) were used in this study. Written informed 
consent was obtained from all participants. Both the medical ethics committee of the Erasmus MC University 
Medical Center Rotterdam and University Medicine Greifswald approved the study. All methods were performed 
in accordance with the relevant guidelines and regulations, approved by the medical ethics committee.
Phenotype definition. Serologic H. pylori colonization in individuals from SHIP, SHIP-TREND, and 
RS was defined by measuring IgG antibody levels in serum using commercial enzyme-linked immunosorbent 
assay (Pyloriset EIA-G III ELISA; Orion). Seropositivity was defined as an anti-H. pylori IgG titer of ≥20 U/mL 
Model Cohort Meta-analysis
H. pylori titer~BMI gene score RS SHIP SHIP-TREND Beta (95% CI) p-value
BMI gene score – crude + + + 0.12 (−0.63; 0.87) 0.76
BMI gene score – adjusted1 + − + 0.03 (−0.71; 0.77) 0.95
BMI gene score – adjusted2 + − + 0.04 (−0.71; 0.78) 0.92
H. pylori positivity~BMI gene score OR (95% CI)
BMI gene score – crude + + − 1.01 (1.00; 1.02) 0.14
BMI gene score – adjusted1 + + − 1.01 (1.00; 1,02) 0.20
BMI gene score – adjusted2 + + − 1.01 (1.00; 1,02) 0.15
H. pylori titer~Obesity gene score Beta (95% CI)
Obesity gene score – crude + + − 0.76 (0.02; 1.50) 0.04
Obesity gene score – adjusted1 + + − 0.73 (−0.00; 1.47) 0.05
Obesity gene score – adjusted2 + + − 0.71 (−0.03; 1.45) 0.06
H. pylori positivity~Obesity gene score OR (95% CI)
Obesity gene score – crude + + − 1.01 (1.00; 1.02) 0.12
Obesity gene score – adjusted1 + + − 1.01 (1.00; 1.02) 0.14
Obesity gene score – adjusted2 + + − 1.01 (1.00; 1.02) 0.15
Table 3. Mendelian randomization H. pylori and BMI/obesity gene score – meta-analysis. 1Adjusted for age 
and sex. 2Adjusted for age, sex, and BMI. ‘−’ means a negative Beta or OR < 0.1. ‘+’ means a positive Beta or 
OR > 0.1.
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according to the manufacturer’s instructions28. Seropositivity is an indicator for current or past colonization. The 
sensitivity of the Pyloriset EIA-G III ELISA is reported as 97.8%, with a specificity of 58%29. To increase specificity 
and reduce the number of false-positive H. pylori infections, we defined subjects with the 25% highest IgG titers 
as H. pylori cases, and those with the 75% lowest IgG titers as controls9.
We further assessed the presence of H. pylori antigen in stool of subjects from SHIP-TREND by using the H. 
pylori antigen ELISA kit (Immunodiagnostics). For this purpose, 100 mg feces was stored at −20 °C. An optical 
density (OD) ≥ 0.025 at 450 nm was considered evidence of H. pylori infection, according to the manufacturer’s 
recommendation. This test has a sensitivity of 97.7% and specificity of 96.3%. H. pylori stool antigen levels and 
measured anti-H. pylori IgG titers are positively correlated (Spearman ρ = 0.59, p < 0.001)9.
Genetic risk score conduction. For the creation of the genetic risk scores (BMI risk score, obesity risk 
score, H. pylori risk score), we firstly searched the literature for publications of genome-wide association stud-
ies (GWAS) for these traits. A list of SNPs that reached genome-wide significance (P < 5 × 10−8) with BMI or 
binary obesity status in populations of European ancestry was established. Three different strategies were used 
to optimize the SNP selection procedure using a key word search (e.g. BMI) on i) the National Human Genome 
Research Institute (NHGRI) GWAS Catalog (www.genome.gov/gwastudies/) ii) the HuGE Navigator GWAS 
Integrator (www.hugenavigator.net/HuGENavigator/gWAHitStartPage.do) iii) the PubMed database (www.
ncbi.nlm.nih.gov/pubmed). Using this strategy, 45 independent loci were found to be associated with BMI vari-
ation and 48 with binary obesity status. We chose to analyze risk scores for BMI and obesity separately. BMI is a 
phenotype which results in a relatively clean risk score. In contrast, various different definitions have been used 
to define obesity, like BMI ≥ 25, or BMI ≥ 30. For this reason we used both phenotypes (e.g. BMI continuous 
and binary) in our analyses. A genotype score (GS) was calculated by summing the alleles of BMI / obesity / H. 
pylori status-associated SNPs. An unweighted GS was used as previously recommended by Dudbridge et al.30. 
Imputed genotypes (1000 G PhaseIv3) were used for the creation of the GS. All GWAS published before June 2014 
were included. Per genetic locus, 1 SNP was selected based on the following criteria: 1) SNP genotyped with an 
imputation quality (R2) of 0.3 or higher in all populations; 2) Preference for A/C or G/T variants to avoid strand 
issues. A list of all studies and variants considered, as well as the variants selected can be found in Supplementary 
Tables S6, S7 and S8.
Statistical analysis. In total, we used three different approaches to assess the relationship between H. pylori 
status and BMI/obesity. First, cross-sectional analyses were performed to assess the relationship between H. pylori 
colonization and BMI/obesity at time of inclusion, by using linear and logistic regression. Outcomes were defined 
as continuous BMI, binary obesity (BMI ≥ 30 kg/m2, with BMI < 30 kg/m2 as reference group), and obesity classes 
(lean BMI < 18.5 kg/m2; normal-weight BMI ≥ 18.5 and <25 kg/m2; overweight BMI ≥ 25 and <30 kg/m2; class 
I obesity BMI ≥ 30 and <35 kg/m2; class II obesity BMI ≥ 35 and <40 kg/m2, class III obesity BMI ≥ 40 kg/m2). 
The latter outcome was defined as a continuous variable with value ‘0’ for lean, and value ‘5’ for class III obesity. 
Unadjusted effects of H. pylori titer or antigen (continuous) and H. pylori positivity (binary phenotype) were 
assessed for each outcome. We additionally adjusted for sex and age. All analyses were done separately for RS, 
SHIP, and SHIP-TREND. A meta-analysis was performed to observe the combined effect of H. pylori colonization 
on BMI/obesity.
Second, a Mendelian randomization approach was carried out to explore a bi-directional link between H. 
pylori colonization and BMI. Linear regression analysis was used to assess the relationship between BMI gene 
score and H. pylori titer and H. pylori positivity. Analyses were first adjusted for sex, age, and additionally for 
BMI at baseline. The same analyses were done regarding the obesity gene score. Linear regression analysis was 
Model Cohort Meta-analysis
BMI~H. pylori gene score RS SHIP SHIP-TREND Beta (95% CI) p-value
Hp gene score – crude − − − −0.05 (−0.16; 0.07) 0.43
Hp gene score – adjusted1 − − − −0.06 (−0.17; 0.05) 0.31
Hp gene score – adjusted2 − − − −0.05 (−0.17; 0.06) 0.37
Obesity3~H. pylori gene score OR (95% CI)
Hp gene score – crude − + − 0.98 (0.92; 1.05) 0.60
Hp gene score – adjusted1 − − − 0.98 (0.91; 1.04) 0.47
Hp gene score – adjusted2 + − − 0.98 (0.91; 1.05) 0.56
Obesity classes4~H. pylori gene 
score Beta (95% CI)
Hp gene score – crude + − − −0.01 (−0.03; 0.02) 0.54
Hp gene score – adjusted1 + − − −0.01 (−0.03; 0.01) 0.37
Hp gene score – adjusted2 + − − −0.03 (−0.06; 0.01) 0.15
Table 4. Mendelian randomization regarding BMI/obesity and H. pylori gene score – meta-analysis. 
1Adjusted for age and sex. 2Adjusted for age, sex, and H. pylori. 3Obesity defined as BMI ≥ 30 kg/m2. 4Obesity 
classes defined as lean: BMI < 18.5 kg/m2; normal-weight: BMI ≥ 18.5 and <25 kg/m2; overweight: BMI ≥ 25 
and <30 kg/m2; class I obesity: BMI ≥ 30 and <35 kg/m2; class II obesity: BMI ≥ 35 and <40 kg/m2, class III 
obesity: BMI ≥ 40 kg/m2. ‘−’ means a negative Beta or OR < 0.1. ‘+’ means a positive Beta or OR > 0.1.
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also used to examine the effect of the H. pylori gene score with BMI, binary obesity status, and obesity classes, all 
defined at baseline. Analyses were adjusted for sex, and age, and additionally for H. pylori status (binary pheno-
type). Data of the three cohorts were combined and examined by using meta-analysis approach. A p-value < 0.05 
was considered to be statistically significant.
All measures of associations are presented as Odds Ratios (OR) or Beta’s with their 95% confidence intervals 
(CI). Statistical analyses were performed using IBM SPSS Statistics 21.0 for Windows (SPSS IBM, Armonk, New 
York, USA). Meta-analyses were done with R library meta (R Core Team (2014), R Foundation for Statistical 
Computing, Vienna, Austria).
Data availability. Due to ethical restrictions data are available upon request. Interested researchers may 
contact our data management team (secretariat.epi@erasmusmc.nl) for access to sensitive data.
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